PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
32.15%
Cash & equivalents growing 32.15% while AGEN's declined -19.88%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
32.15%
Below half of AGEN's -19.88%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.78%
Below half of AGEN's -16.63%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-2.88%
Below half AGEN's 9.04%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.86%
Below half of AGEN's 0.55%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
30.51%
Below half of AGEN's -10.21%. Michael Burry sees a potential red flag for stagnation or capital shortage.
63.16%
Similar yoy growth to AGEN's 66.12%. Walter Schloss sees parallel payables strategy. Check top-line correlation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.70%
50-75% of AGEN's -45.23%. Bruce Berkowitz notes a more controlled liability line.
49.30%
Above 1.5x AGEN's 17.22%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
49.30%
Above 1.5x AGEN's 0.12%. Michael Burry sees a potential leverage warning sign.
16.87%
Above 1.5x AGEN's 0.78%. Michael Burry suspects heavy new equity expansion or dilution.
-5.16%
≥ 1.5x AGEN's -2.97%. David Dodd sees higher yoy retained profits than competitor.
-13.18%
Less than half of AGEN's 1.92%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
26.52%
Below half AGEN's -85.97%. Michael Burry sees potential underperformance in building shareholder capital.
30.51%
Below half AGEN's -10.21%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-32.15%
Less than half of AGEN's 74.95%. David Dodd sees better deleveraging or stronger cash buildup than competitor.